HOME > TOP STORIES
TOP STORIES
-
BUSINESS AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
-
REGULATORY Business Improvement Order Issued to Novartis Japan
November 13, 2015
-
REGULATORY Chuikyo Subcommittee Broadly OKs Price Maintenance Rule for Essential Drugs
November 12, 2015
-
BUSINESS Top 4 Wholesalers See 7% Sales Rise on Hep C Drugs, but Paltry 0.82% in Operating Margin
November 11, 2015
-
REGULATORY Novartis Fails to Report Nearly 5,500 Side Effect Cases, Biz Improvement Order Likely This Month
November 10, 2015
-
REGULATORY Chuikyo Wants to Stick to 14-Day Prescription Limit
November 9, 2015
-
BUSINESS Half-Year Revenues of 4 Japanese Majors Beat Projections on Buoyant Global Products
November 6, 2015
-
REGULATORY Chuikyo Doctor Reps Positive, but Payers Wary about Industry’s Ideas on “Essential Drugs”
November 5, 2015
-
REGULATORY Pricing Rule for Essential Drugs Top Priority in FY2016 Reform: Ex-MHLW Economic Affairs Head
November 4, 2015
-
REGULATORY MHLW Weighs Another Business Improvement Order to Novartis
November 4, 2015
-
BUSINESS Sakigake Designation System Very Useful: Astellas President
November 2, 2015
-
REGULATORY MOF Proposes Full Implementation of Cost-Effective Assessments as Precondition for Full-Scale Introduction of Premium for New Drug Development
November 2, 2015
-
TRENDS Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
October 30, 2015
-
REGULATORY Chuikyo Sees Big Chorus for Further Reforms in Generic Pricing
October 29, 2015
-
REGULATORY MHLW Eager to Expedite Commercialization of Sakigake Products: New Bureau Head
October 28, 2015
-
BUSINESS Shift to Specialty - 4: Ceolia Pharma Aims to Be Single-Source Provider in Field of ENT
October 28, 2015
-
REGULATORY 6 Drugs Get Sakigake Designation for Fast-Track Review
October 27, 2015
-
BUSINESS Jardiance Cardiovascular Data Boon for Japan’s Floundering SGLT-2 Inhibitor Space?
October 26, 2015
-
REGULATORY MHLW Asks Chuikyo to Revise Evaluation for Antipsychotic Therapies in Large Dosages without Adequate Guidance
October 26, 2015
-
BUSINESS Sandoz Looking to Emerge as Top Foreign Generic Maker in Japan in 5 Years
October 23, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
